Mehta Antibiotics Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
- Paid Up Capital ₹ 1.30 M
- Company Age 13 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 20.00 Cr
- Revenue Growth -44.55%
- Profit Growth 161.76%
- Ebitda 7.91%
- Net Worth 373.86%
- Total Assets -2.83%
About Mehta Antibiotics
Mehta Antibiotics Private Limited (MAPL) is a Private Limited Indian Non-Government Company incorporated in India on 01 March 2011 and has a history of 13 years and 11 months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 1.30 M.
The company currently has active open charges totaling ₹20.00 Cr.
Atul Mehta and Chetan Mehta serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74900MH2011PTC214255
- Company No.
214255
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Mar 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Mehta Antibiotics?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Atul Mehta  | Director | 01-Mar-2011 | Current |
| Chetan Mehta | Director | 01-Mar-2011 | Current |
Financial Performance of Mehta Antibiotics.
Mehta Antibiotics Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 44.55% decrease. The company also saw a substantial improvement in profitability, with a 161.76% increase in profit. The company's net worth Soared by an impressive increase of 373.86%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mehta Antibiotics?
Unlock access to Mehta Antibiotics's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹200.00 M
₹0
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 10.00 Cr
- Others : 10.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 01 Nov 2022 | Others | ₹10.00 Cr | Open |
| 09 Mar 2018 | Hdfc Bank Limited | ₹10.00 Cr | Open |
How Many Employees Work at Mehta Antibiotics?
Unlock and access historical data on people associated with Mehta Antibiotics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mehta Antibiotics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mehta Antibiotics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
